Gut Microbiota and Cancer: From Pathogenesis to Therapy
Authors:
- Silvia VivarelliSilvia Vivarelli
- Rossella SalemiRSRossella Salemi
- Saverio CandidoSaverio Candido
- Luca FalzoneLuca Falzone
- Maria SantagatiMSMaria Santagati
- Stefania StefaniSSStefania Stefani
- Francesco TorinoFTFrancesco Torino
- Giuseppe Luigi BannaGiuseppe Luigi Banna
- Giuseppe ToniniGTGiuseppe Tonini
- Massimo LibraMassimo Libra
Top Cited Papers
Open Access
Abstract
Cancer is a multifactorial pathology and it represents the second leading cause of death worldwide. In the recent years, numerous studies highlighted the dual role of the gut microbiota in preserving host’s health. Gut resident bacteria are able to produce a number of metabolites and bioproducts necessary to protect host’s and gut’s homeostasis. Conversely, several microbiota subpopulations may expand during pathological dysbiosis and therefore produce high levels of toxins capable, in turn, to trigger both inflammation and tumorigenesis. Importantly, gut microbiota can interact with the host either modulating directly the gut epithelium or the immune system. Numerous gut populating bacteria, called probiotics, have been identified as protective against the genesis of tumors. Given their capability of preserving gut homeostasis, probiotics are currently tested to help to fight dysbiosis in cancer patients subjected to chemotherapy and radiotherapy. Most recently, three independent studies show that specific gut resident species may potentiate the positive outcome of anti-cancer immunotherapy. The highly significant studies, uncovering the tight association between gut microbiota and tumorigenesis, as well as gut microbiota and anti-cancer therapy, are here described. The role of the Lactobacillus rhamnosus GG (LGG), as the most studied probiotic model in cancer, is also reported. Overall, according to the findings here summarized, novel strategies integrating probiotics, such as LGG, with conventional anti-cancer therapies are strongly encouraged.Keywords
This publication has 203 references indexed in Scilit:
- Gut Microbiota Composition in Male Rat Models under Different Nutritional Status and Physical Activity and Its Association with Serum Leptin and Ghrelin LevelsPLOS ONE, 2013
- Inflammasomes in carcinogenesis and anticancer immune responsesNature Immunology, 2012
- Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesityNature, 2012
- Microbiome and MalignancyCell Host & Microbe, 2011
- NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for ColitisCell, 2011
- The Nlrp3 inflammasome: contributions to intestinal homeostasisTrends in Immunology, 2011
- The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental ColitisImmunity, 2010
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesisNature Immunology, 2009
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006